Diabetes mellitus type 2 correction, changes in c-peptidemia and insulinemia inconnection with ileoduodenoplasty
DOI:
https://doi.org/10.34287/MMT.3(42).2019.8Abstract
Purpose of the study. The diabetes move changes estimate and c-peptidemia and insulinemia levels changes in connection with ileoduodenoplasty.
Materials and methods. C-peptiemia and insulinemia were estimated in 45 patients with diabetes mellitus type 2. There were 20 men, 25 women, mean (M ± m) age 27,4 ± 9,5 years. Body mass index was from 23,4 to 61,4 kg/cm2.
For glycemia correction pill medication use 12 patients, insulin injection 18, first revealed diabetes or insulin resistance with poorly corrected hypertension and cardiac insufficiency of 2 stage have 15 patients. Mean (M ± m) diabetic duration was 15,1 ± 7,7 years.
Results. At 3 weeks since surgery glycemia correction by means of metformin was necessary in 6 patients, other do not need any diabetes correction. In terms 1–3, 4–6, 7–21 day, 22 day – 3 months, 3–12 months since surgery mean values of studied hormones declined gradually. In spite of this, declining in hormones level were unproportional one to another, in some patients it increases or changes in inverse mode: raising in insulinemia coincidence with decline in c-peptidemia and vice versa.
Conclusion. Performing of ileoduodenoplasty lead to disappear of insulin resistance in few days since surgery.
In term 3 weeks since surgery steady compensation of diabetes mellitus 2 type occur.
Ambiguous changes in c-peptidemia and insulinemia levels both in early and late terms since surgery already not in equivalence with glycemia point out at its interrelation with other regulators of food consumption.
References
Hayoz C, Hermann T, Raptis DA et al. Comparison of metabolic outcomes in patients undergoing laparoscopic roux-en-Y gastric bypass versus sleeve gastrectomy a systematic review and meta-analysis of randomised controlled trials.Swiss Med Wkly. 2018; 148: w14633. DOI: 10.4414/smw.2018.14626. eCollection 2018.
Martin WP, Docherty NG, Le Roux CW. Impact of bariatric surgery on cardiovascular and renal complications of diabetes: a focus on clinical outcomes and putative mechanisms. Expert Rev Endocrinol Metab. 2018; 13 (5): 251–262. DOI: 10.1080/17446651.2018.1518130.
van de Laar AW, de Brauw LM, Meesters EW. Relationships between type 2 diabetes remission after gastric bypass and different weight loss metrics: arguments against excess weight loss in metabolic surgery. Surg Obes Relat Dis. 2016; 12 (2): 274–82. DOI: 10.1016/j.soard.2015.07.005.
Qiu NC, Li W, Liu ME et al. Comparison of Great Curvature Plication with Duodenal-Jejunal Bypass (GCP-DJB) and Sleeve Gastrectomy (SG) on Metabolic Indices and Gut Hormones in Type 2 Diabetes Mellitus Rats Obes Surg. 2018; 28 (12): 4014-4021. DOI: 10.1007/s11695-018-3459-6.
Yan W, Bai R, Li Y et al. Analysis of Predictors of Type 2 Diabetes Mellitus Remission After Roux-en-Y Gastric Bypass in 101 Chinese Patients. Obes Surg. 2019; 29 (6): 1867–1873. DOI: 10.1007/s11695-019-03783-x.
Park JY. Prediction of Type 2 Diabetes Remission after Bariatric or Metabolic Surgery. J Obes Metab Syndr. 2018; 27 (4): 213–222. DOI: 10.7570/jomes.2018.27.4.213.
Zhao L, Li W, Su Z et al. Preoperative Fasting C-Peptide Predicts Type 2 Diabetes Mellitus Remission in Low-BMI Chinese Patients After Rouxen-Y Gastric Bypass. J Gastrointest Surg. 2018; 22 (10): 1672–1678. DOI: 10.1007/s11605-018-3818-6.
Howard ML, Steuber TD, Nisly SA. Glycemic Management in the Bariatric Surgery Population: A Review of the Literature. Pharmacotherapy. 2018; 38 (6): 663–673. DOI: 10.1002/phar.2120.
Beli E, Yan Y, Moldovan L, Vieira CP et al. Restructuring of the Gut Microbiome by Intermittent Fasting Prevents Retinopathy and Prolongs Survival in db/db Mice. Diabetes. 2018; 67 (9): 1867–1879. DOI: 10.2337/db18-0158.
Souteiro P, Belo S, Neves JS et al. Preoperative Beta Cell Function Is Predictive of Diabetes Remission After Bariatric Surgery. Obes Surg. 2017; 27 (2): 288-294. DOI: 10.1007/s11695-016-2300-3.
Mallipedhi A, Min T, Prior SL et al. Association between the preoperative fasting and postprandial C-peptide AUC with resolution of type 2 diabetes 6 months following bariatric surgery. Metabolism. 2015; 64 (11): 1556–1563. DOI: 10.1016/j.metabol.2015.08.009.
Zachariah P, Chen CY, Lee WJ et al. Compared to Sleeve Gastrectomy, Duodenal-Jejunal Bypass with Sleeve Gastrectomy Gives Better Glycemic Control in T2DM Patients, with a Lower ß-Cell Response and Similar Appetite Sensations: MixedMeal Study. Obes Surg. 2016; 26 (12): 2862–2872. DOI: 10.1007/s11695-016-2205-1.
Aminian A, Brethauer SA, Daigle CR et al. Outcomes of bariatric surgery in type 2 diabetic patients with diminished pancreatic secretory reserve. Acta Diabetol. 2014; 51 (6): 1077–1079. DOI: 10.1007/s00592-014-0642-7.
Nor Hanipah Z, Punchai S, Birriel TJ et al. Clinical features of symptomatic hypoglycemia observed after bariatric surgery. Surg Obes Relat Dis. 2018; 14 (9): 1335–1339. DOI: 10.1016/j.soard.2018.02.022.
Yan Y, Sha Y, Huang X et al. Roux-en-Y Gastric Bypass Improves Metabolic Conditions in Association with Increased Serum Bile Acids Level and Hepatic Farnesoid X Receptor Expression in a T2DM Rat Model. Obes Surg. 2019. DOI: 10.1007/s11695-019-03918-0.
Khorgami Z, Shoar S, Saber AA et al. Outcomes of Bariatric Surgery Versus Medical Management for Type 2 Diabetes Mellitus: a Meta-Analysis of Randomized Controlled Trials. Obes Surg. 2019; 29 (3): 964–974. DOI: 10.1007/s11695-018-3552-x.
Shah A, Holter MM, Rimawi F et al. Insulin Clearance After Oral and Intravenous Glucose Following Gastric Bypass and Gastric Banding Weight Loss. Diabetes Care. 2019; 42 (2): 311–317. DOI: 10.2337/dc18-1036.
Jahansouz C, Xu H, Kizy S et al. Serum FABP4 concentrations decrease after Roux-en-Y gastric bypass but not after intensive medical management. Surgery. 2019; 165 (3): 571–578. DOI: 10.1016/j.surg.2018.08.007.
Cortez RV, Petry T, Caravatto P et al. Shifts in intestinal microbiota after duodenal exclusion favor glycemic control and weight loss: a randomized controlled trial. Surg Obes Relat Dis. 2018; 14 (11): 1748–1754. DOI: 10.1016/j.soard.2018.07.021.
Previti E, Salinari S, Bertuzzi A et al. Glycemic control after metabolic surgery: a Granger causality and graph analysis. Am J Physiol Endocrinol Metab. 2017; 313 (5): E622–E630. DOI: 10.1152/ajpendo.00042.2017.
Shao-Wei Xiong, Jing Cao, Xian-Ming Liuet et al. Effect of Modified Roux-en-Y Gastric Bypass Surgery on GLP-1, GIP in Patients with Type 2 Diabetes Mellitus. Gastroenterology Research and PracticeVolume 2015, Article ID 625196, 4 pages. http://dx.doi.org/10.1155/2015/625196.
Laubner K, Riedel N, Fink Ketal. Comparative efficacy and safety of the duodenal-jejunal bypass liner in obese patients with type 2 diabetes mellitus: A case control study. Diabetes Obes Metab. 2018; 20 (8): 1868–1877. DOI: 10.1111/dom.13300.
